D-Lactic Acid as a Metabolite: Toxicology, Diagnosis, and Detection

Pohanka, Miroslav

doi:10.1155/2020/3419034

Cited by 123 publications

(92 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…D-lactic acid is a metabolite produced by bacterial fermentation [ 68 ]. Many kinds of bacteria in the intestine can produce D-lactic acid [ 68 ].…”

Section: Resultsmentioning

confidence: 99%

“…D-lactic acid is a metabolite produced by bacterial fermentation [ 68 ]. Many kinds of bacteria in the intestine can produce D-lactic acid [ 68 ]. When the intestinal barrier function is impaired, a large amount of D-lactic acid in the intestine can enter the blood circulation system through the damaged intestinal mucosa [ 68 ].…”

Section: Resultsmentioning

confidence: 99%

“…Many kinds of bacteria in the intestine can produce D-lactic acid [ 68 ]. When the intestinal barrier function is impaired, a large amount of D-lactic acid in the intestine can enter the blood circulation system through the damaged intestinal mucosa [ 68 ]. Therefore, monitoring D-lactate levels in the blood can promptly reflect the changes in intestinal mucosal damage and permeability.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Enteral nutrition modulation with n-3 PUFAs directs microbiome and lipid metabolism in mice

Tao

Xing

et al. 2021

PLoS ONE

View full text Add to dashboard Cite

Nutritional support using exclusive enteral nutrition (EEN) has been studied as primary therapy for the management of liver diseases, Crohn’s disease, and cancers. EEN can also increase the number of beneficial microbiotas in the gut, improve bile acid and lipid metabolism, and decrease the number of harmful dietary micro-particles, possibly by influencing disease occurrence and increasing immunity. This study investigated the effects of EEN-n-3 polyunsaturated fatty acids (3PUFAs) (EEN-3PUFAs) on the gut microbiome, intestinal barrier, and lipid or bile acid metabolism in mice. Metagenomic sequencing technology was used to analyze the effects of EEN-3PUFAs on the composition of gut microbiome signatures. The contents of short-chain fatty acids (SCFAs) and bile acids in the feces and liver of the mice were assayed by gas chromatography and ultra-high-pressure liquid chromatography/high-resolution tandem mass spectrometry, respectively. The levels of lipopolysaccharide (LPS) and D-lactic acid in the blood were used to assess intestinal permeability. The results indicated that EEN-3PUFAs could improve the composition of gut microbiome signatures and increase the abundance of Barnesiella and Lactobacillus (genus), Porphyromonadaceae, and Bacteroidia (species), and Bacteroidetes (phylum) after EEN-3PUFAs initiation. In addition, EEN-3PUFAs induced the formation of SCFAs (mainly including acetic acid, propionic acid, and butyric acid) and increased the intestinal wall compared to the control group. In conclusion, EEN-3PUFAs modulate the alterations in gut microbiome signatures, enhanced intestinal barrier, and regulated the fatty acid composition and lipid metabolism shifts and the putative mechanisms underlying these effects.

show abstract

“…D-lactic acid is a metabolite produced by bacterial fermentation [ 68 ]. Many kinds of bacteria in the intestine can produce D-lactic acid [ 68 ].…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Enteral nutrition modulation with n-3 PUFAs directs microbiome and lipid metabolism in mice

Tao

Xing

et al. 2021

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…All concentrations of the active compounds were derived from previous published studies and DMD hiPSC-CMs were treated for 5 days prior to functional assay. Specifically: Quercetin, Naringenin, Kaempferol, and Hesperidin were used at 10 μM ( Gutiérrez-Venegas et al, 2014 ; Denaro et al, 2021 ); Diosgenin at 200 ng/mL ( Zhao et al, 2018 ); D -lactic acid at 10 μM ( Pohanka, 2020 ); Vitamin C at 10 μM ( Parra-Flores et al, 2019 ); Oxalic acid (10 μM) ( Liu et al, 2018 ); and Allicin at 10 μM ( Xiang et al, 2020 ).…”

Section: Methodsmentioning

confidence: 99%

Targeting of CAT and VCAM1 as Novel Therapeutic Targets for DMD Cardiomyopathy

Xiong

Liang

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Duchenne muscular dystrophy (DMD) related cardiomyopathy is the leading cause of early mortality in DMD patients. There is an urgent need to gain a better understanding of the disease molecular pathogenesis and develop effective therapies to prevent the onset of heart failure. In the present study, we used DMD human induced pluripotent stem cells (DMD-hiPSCs) derived cardiomyocytes (CMs) as a platform to explore the active compounds in commonly used Chinese herbal medicine (CHM) herbs. Single CHM herb (DaH, ZK, and CQZ) reduced cell beating rate, decreased cellular ROS accumulation, and improved structure of DMD hiPSC-CMs. Cross-comparison of transcriptomic profiling data and active compound library identified nine active chemicals targeting ROS neutralizing Catalase (CAT) and structural protein vascular cell adhesion molecule 1 (VCAM1). Treatment with Quecetin, Kaempferol, and Vitamin C, targeting CAT, conferred ROS protection and improved contraction; treatment with Hesperidin and Allicin, targeting VCAM1, induced structure enhancement via induction of focal adhesion. Lastly, overexpression of CAT or VCAM1 in DMD hiPSC-CMs reconstituted efficacious effects and conferred increase in cardiomyocyte function. Together, our results provide a new insight in treating DMD cardiomyopathy via targeting of CAT and VCAM1, and serves as an example of translating Bed to Bench back to Bed using a muti-omics approach.

show abstract

“…Some lactic acid bacteria can produce a mixture of L-and D-lactate (Stiles and Holzapfel 1997). Although D-lactate is not a highly toxic compound, D-lactate accumulation in blood (i.e., 3 > mmol/L, Petersen, 2005) might cause health problems due to (Pohanka 2020;Puwanant et al 2005). However, more recent studies have shown that D-lactate accumulation may only occur in cases of impaired Dlactate metabolism or a disturbed gastrointestinal function following any clinical symptoms, including short bowel syndrome (Connolly et al 2005;Ku et al 2006).…”

Section: Biogenic Amines and Lactate Productionmentioning

confidence: 99%

Safety assessment of Lactobacillus reuteri IDCC 3701 based on phenotypic and genomic analysis

et al. 2021

View full text Add to dashboard Cite

Purpose Lactobacillus reuteri is one of the most largely studied human-commensal bacteria and widely used as a form of probiotics. Safety of probiotics has become increasingly important for human consumption due to increasing health-concerns in food industry. In this study, the safety of L. reuteri IDCC 3701 isolated from human breast milk was thoroughly investigated. Methods Whole-genome sequence analysis was performed to identify antibiotic resistance and toxigenicity of L. reuteri IDCC 3701. Phenotypic analysis such as minimal inhibitory concentration, β-hemolysis, extracellular enzyme activity, and the production of biological amines and L/D-lactate, was investigated. Finally, acute oral toxicity test was performed to access L. reuteri IDCC 3701 safety. Results Although multiple resistances to gentamicin and kanamycin were observed in L. reuteri IDCC 3701, it was revealed that these resistances are intrinsic and not transferable through whole-genome analysis. In addition, various phenotypic analysis concerning hemolysis, enzyme activity, and D-lactate production did not show any negative results. Although L. reuteri IDCC 3701 harbors a histidine decarboxylase gene, no biogenic amines were detected. Finally, L. reuteri IDCC 3701 exhibited no evidence of acute toxicity according to an in vivo study. Conclusion Our findings demonstrate that L. reuteri IDCC 3701 is considered to be safe for human consumption as probiotics based on the in silico, in vitro and in vivo studies.

show abstract

D-Lactic Acid as a Metabolite: Toxicology, Diagnosis, and Detection

Cited by 123 publications

References 105 publications

Enteral nutrition modulation with n-3 PUFAs directs microbiome and lipid metabolism in mice

Enteral nutrition modulation with n-3 PUFAs directs microbiome and lipid metabolism in mice

Targeting of CAT and VCAM1 as Novel Therapeutic Targets for DMD Cardiomyopathy

Safety assessment of Lactobacillus reuteri IDCC 3701 based on phenotypic and genomic analysis

Contact Info

Product

Resources

About